Legal & General Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Legal & General Group’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-7,296	Closed	-$27K	–	3299
2017 Q4	$27K	Buy	7,296 +2,320	+47%	+$9.5K	﹤0.01%	3098
2017 Q3	$20K	Hold	4,976	–	–	﹤0.01%	3180
2017 Q2	$18K	Buy	+4,976	New	+$19.7K	﹤0.01%	3230
2016 Q2	–	Sell	-3,199	Closed	-$24K	–	2945
2016 Q1	$24K	Hold	3,199	–	–	﹤0.01%	2643
2015 Q4	$43K	Hold	3,199	–	–	﹤0.01%	2533
2015 Q3	$52K	Hold	3,199	–	–	﹤0.01%	2432
2015 Q2	$72K	Buy	+3,199	New	+$50.6K	﹤0.01%	2356

Legal & General Group's CASC Position: Q1 2018 in Review

Legal & General Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 7,296 shares — an estimated $27K sold.

Legal & General Group first reported a position in CASC in Q2 2015 and held it in 7 quarters. The position peaked at $72K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Legal & General Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Legal & General Group sold 7,296 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $27K.
Legal & General Group first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 7 quarters.
Legal & General Group's Cascadian Therapeutics, Inc. position peaked at $72K in Q2 2015.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Legal & General Group's 13F filing for Q1 2018, filed 17 May 2018.